Voyager Therapeutics Valuation
| VYGR Stock | USD 3.88 0.21 5.13% |
At this time, the company appears to be undervalued. Voyager Therapeutics has a current Real Value of $4.42 per share. The regular price of the company is $3.88. Our model measures the value of Voyager Therapeutics from inspecting the company fundamentals such as Operating Margin of (6.10) %, return on equity of -0.24, and Shares Outstanding of 55.21 M as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Voyager Therapeutics' valuation include:
Price Book 0.7137 | Enterprise Value | Enterprise Value Ebitda 2.5901 | Price Sales 2.6775 | Enterprise Value Revenue 0.1431 |
Undervalued
Today
Please note that Voyager Therapeutics' price fluctuation is relatively risky at this time. Calculation of the real value of Voyager Therapeutics is based on 3 months time horizon. Increasing Voyager Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Voyager stock is determined by what a typical buyer is willing to pay for full or partial control of Voyager Therapeutics. Since Voyager Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Voyager Stock. However, Voyager Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.88 | Real 4.42 | Target 17.1 | Hype 3.88 | Naive 3.83 |
The intrinsic value of Voyager Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Voyager Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Voyager Therapeutics helps investors to forecast how Voyager stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Voyager Therapeutics more accurately as focusing exclusively on Voyager Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Voyager Therapeutics' intrinsic value based on its ongoing forecasts of Voyager Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Voyager Therapeutics' closest peers.
Voyager Therapeutics Cash |
|
Voyager Valuation Trend
Voyager Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Voyager Therapeutics' financial worth over time. Using both Voyager Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Voyager Therapeutics Total Value Analysis
Voyager Therapeutics is at this time forecasted to have valuation of (9.03 M) with market capitalization of 214.2 M, debt of 43.73 M, and cash on hands of 148.06 M. The negative valuation of Voyager Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Voyager Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(9.03 M) | 214.2 M | 43.73 M | 148.06 M |
Voyager Therapeutics Investor Information
About 64.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.71. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Voyager Therapeutics recorded a loss per share of 1.13. The entity had not issued any dividends in recent years. Based on the key indicators related to Voyager Therapeutics' liquidity, profitability, solvency, and operating efficiency, Voyager Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Voyager Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Voyager Therapeutics has an asset utilization ratio of 20.35 percent. This connotes that the Company is making $0.2 for each dollar of assets. An increasing asset utilization means that Voyager Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Voyager Therapeutics Ownership Allocation
Voyager Therapeutics shows a total of 55.21 Million outstanding shares. Over half of Voyager Therapeutics' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Voyager Therapeutics Profitability Analysis
The company reported the previous year's revenue of 80 M. Net Loss for the year was (65 M) with loss before overhead, payroll, taxes, and interest of (47.37 M).About Voyager Therapeutics Valuation
The stock valuation mechanism determines Voyager Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Voyager Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Voyager Therapeutics. We calculate exposure to Voyager Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Voyager Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 80 M | 55.6 M | |
| Pretax Profit Margin | (0.80) | (0.84) | |
| Operating Profit Margin | (1.04) | (1.09) | |
| Net Loss | (0.81) | (0.85) | |
| Gross Profit Margin | 0.88 | 0.93 |
Voyager Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Voyager Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 57.7 M |
Voyager Therapeutics Current Valuation Indicators
Voyager Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Voyager Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Voyager Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Voyager Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Voyager Therapeutics' worth.Additional Tools for Voyager Stock Analysis
When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.